Phase 1-2 trial of trametinib with or without dabrafenib for pediatric BRAFV600-mutant low-grade glioma

BRAFV600 mutations occur in many childhood cancers, including approximately 20% of low-grade glioma’s (LGGs). A multinational phase 1-2 trial found age-based and weight-based safe and effective doses of trametinib monotherapy and trametinib-dabrafenib combination therapy for pediatric BRAFV600-mutant LGG.